SAN DIEGO — Adults with type 2 diabetes naive to insulin therapy saw a long-term reduction in HbA1c and superior time in the recommended glucose range with once-weekly insulin icodec compared with daily insulin glargine, data show.ONWARDS 1, the longest trial in the ONWARDS development program for insulin icodec (Novo Nordisk), showed that the novel weekly insulin regimen facilitated the
Data from a pair of phase 3a trials presented at ADA 2023 provide clinicians with new insight into the effects of once-weekly insulin icodec relative to daily insulin degludec.
New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety and efficacy of AT-001 (caficrestat) in improving or preventing worsening of cardiac functional capacity in Diabetic Cardiomyopathy (DbCM); topline data from the study is expected.